Is Akums Drugs and Pharmaceuticals a Good Buy After Its Q1 FY27 Results?

Akums Drugs and Pharmaceuticals share price around Rs 759. 4.7% below 52-week high of Rs 797. Q1 FY27 revenue Rs 1,197 crore, up 13.9% YoY. PAT Rs 101 crore, up 56.1%. PE 41x.

The Akums Drugs and Pharmaceuticals share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Akums Drugs and Pharmaceuticals is one of India’s largest pharmaceutical CDMOs, manufacturing formulations for other drugmakers, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 1,197 crore, up 13.9% year on year, while profit after tax came in at Rs 101 crore, up 56.1% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Akums Drugs and Pharmaceuticals share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Akums Drugs and Pharmaceuticals share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Akums Drugs and Pharmaceuticals Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 1,197 crore	Rs 1,051 crore	13.9%
EBITDA	Rs 205 crore	Rs 156 crore	31.7%
Operating Margin	17.6%	15.2%	NA
Profit Before Tax	Rs 139 crore	Rs 96 crore	45.6%
Net Profit / (Loss)	Rs 101 crore	Rs 65 crore	56.1%

Akums Drugs and Pharmaceuticals Q1 FY27 Performance Analysis

Check Akums Drugs and Pharmaceuticals Fundamentals on Univest Screener

Revenue growth of 13.9% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmaceutical contract development and manufacturing (CDMO) sector.

The bigger story is on profitability. PAT grew 56% to Rs 101 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the Akums Drugs and Pharmaceuticals share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.

On a sequential basis, revenue moved up 0.3% sequentially from Rs 1,193 crore in the March 2026 quarter and net profit moved up 24.1% sequentially from Rs 81 crore in the prior quarter, giving a fuller picture of the trend behind the Akums Drugs and Pharmaceuticals share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Akums Drugs and Pharmaceuticals’ revenue grew 13.9% year on year this quarter, taking the quarterly base to Rs 1,197 crore in a pharmaceutical contract development and manufacturing (CDMO) business that remains sensitive to demand and pricing cycles that ultimately feed through to the Akums Drugs and Pharmaceuticals share price.

Margin Movement

EBITDA rose 31.7% to Rs 205 crore, and operating margin moved to 17.6% from 15.2% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

Akums Drugs and Pharmaceuticals carries a low debt-to-equity ratio of 0.05, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

The stock trades at a PE of 41.2x against an industry average of 37.7x, a premium that this quarter’s results will need to justify going forward.

Dividend Details

No interim dividend was declared alongside Akums Drugs and Pharmaceuticals’ Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.38%, based on dividends paid over the last year. Investors tracking the Akums Drugs and Pharmaceuticals share price for income should watch the company’s announcements around its next annual results for any dividend decision.

Akums Drugs and Pharmaceuticals Share Price Outlook for FY27

The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Akums Drugs and Pharmaceuticals can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter’s momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.

For the Akums Drugs and Pharmaceuticals share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter’s pace, since any slowdown would put pressure on a stock priced for continued strength.

Akums Drugs and Pharmaceuticals Stock Performance

Download the Univest iOS App or Univest Android App to track Akums Drugs and Pharmaceuticals’ live share price and get daily stock updates.

The Akums Drugs and Pharmaceuticals share price was trading around Rs 759 as results season played out in late August 2026, roughly 4.7% below its 52-week high of Rs 797 and well above its 52-week low of Rs 409.

The Akums Drugs and Pharmaceuticals share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 7.70% and a book value of around Rs 211 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Valuation Risk

At 41.2x earnings against an industry average of 37.7x, the stock leaves little room for disappointment if growth slows.

Sector and Demand Risk

As a pharmaceutical contract development and manufacturing (CDMO) business, Akums Drugs and Pharmaceuticals’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Akums Drugs and Pharmaceuticals share price well before the next result.

Execution Risk

Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Akums Drugs and Pharmaceuticals’ Q1 FY27 results were genuinely strong, with revenue at Rs 1,197 crore and PAT up 56% to Rs 101 crore. That said, at a PE of 41.2x, the Akums Drugs and Pharmaceuticals share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Akums Drugs and Pharmaceuticals is a good buy should weigh the strong quarter against the valuation before adding at current levels. The Akums Drugs and Pharmaceuticals share price remains the number to track heading into the next quarterly update. The Akums Drugs and Pharmaceuticals share price remains the number to track heading into the next quarterly update. The Akums Drugs and Pharmaceuticals share price remains the number to track heading into the next quarterly update.

Frequently Asked Questions on Akums Drugs and Pharmaceuticals Q1 FY27 Results

What were Akums Drugs and Pharmaceuticals’ Q1 FY27 results?

Ans. Akums Drugs and Pharmaceuticals reported Q1 FY27 revenue of Rs 1,197 crore, up 13.9% year on year, and PAT of Rs 101 crore, up 56.1% year on year.

Is Akums Drugs and Pharmaceuticals a good buy after its Q1 FY27 results?

Ans. Akums Drugs and Pharmaceuticals’ core numbers improved this quarter, though at a PE of 41.2x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.

What is the Akums Drugs and Pharmaceuticals share price today?

Ans. The Akums Drugs and Pharmaceuticals share price was trading around Rs 759 in late August 2026, about 4.7% below its 52-week high of Rs 797 and well above its 52-week low of Rs 409.

What is Akums Drugs and Pharmaceuticals’ revenue and profit for Q1 FY27?

Ans. Akums Drugs and Pharmaceuticals reported revenue of Rs 1,197 crore and a net profit of Rs 101 crore for the quarter ended June 30, 2026.

Did Akums Drugs and Pharmaceuticals declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Akums Drugs and Pharmaceuticals’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

What is Akums Drugs and Pharmaceuticals’ PE ratio and is it expensive?

Ans. The Akums Drugs and Pharmaceuticals share price trades at a trailing PE of 41.2x, against an industry average of 37.7x. Investors should compare this with the company’s growth rate before judging value.

What are the key risks for Akums Drugs and Pharmaceuticals investors right now?

Ans. At 41.2x earnings against an industry average of 37.7x, the stock leaves little room for disappointment if growth slows. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Akums Drugs and Pharmaceuticals’ promoter shareholding?

Ans. Promoter shareholding data for Akums Drugs and Pharmaceuticals was not fully available for this quarter and should be checked on the company’s official filings.